Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Clinical trial NCT06242834 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06242834
- Sponsor
- Northwestern University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-30
- Primary completion
- 2027-04-24
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.